Aduhelm market report points to aging-driven demand and faster Asia-Pacific growth

The Business Research Company says the Aduhelm market is expanding as Alzheimer’s cases rise, diagnosis improves and demand grows for disease-modifying therapies. The report names North America as the largest market in 2025 and expects Asia-Pacific to grow fastest through the forecast period.

Why it matters: - The Aduhelm market is tied to a larger surge in Alzheimer’s care demand as populations age and dementia cases rise. - The report frames Aduhelm as part of a shift toward disease-modifying therapies, biomarker-based diagnosis and earlier intervention. - The market outlook matters for drug makers, clinicians and health systems investing in neurology and neurodegenerative care.

What happened: - The Business Research Company published its Aduhelm Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on October 29, 2026. - The report says Aduhelm, also called aducanumab, is a prescription monoclonal antibody developed by Biogen and Eisai Co., Ltd. - Aduhelm targets amyloid-beta plaques in the brain, which are linked to Alzheimer’s disease progression. - The report highlights demand patterns, regional trends and a 2026-2035 forecast for the market. - The company also offered a free sample of the report and a full version through its website.

The details: - Market growth has been fueled by an aging population, no definitive cure for Alzheimer’s disease, progress in amyloid research, rising dementia cases and more neurological clinical trials. - Future growth drivers include more Alzheimer’s patients, stronger demand for early intervention therapies, wider use of biomarker-based diagnostics, higher neurology investment and next-generation monoclonal antibodies. - The forecast period is expected to be shaped by disease-modifying Alzheimer’s treatments, broader monoclonal antibody use in neurology, more funding for neurodegenerative research, earlier diagnosis and expansion of amyloid-targeted therapies. - The report says Aduhelm aims to slow cognitive decline by reducing amyloid-beta plaques. - The Alzheimer Society in the UK reported in May 2024 that about 982,000 people are living with dementia, with that number projected to reach 1.4 million by 2040. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds new analytical features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample of the Aduhelm market report is available. - The full Aduhelm market report is available online.

Between the lines: - The report is signaling that Aduhelm’s commercial relevance depends less on a single drug story and more on the broader Alzheimer’s treatment market. - North America’s lead suggests established access, awareness and infrastructure still matter most today. - Asia-Pacific’s faster projected growth points to unmet need and rising spending capacity in markets where Alzheimer’s prevalence is climbing.

What's next: - The report expects more uptake of early diagnosis tools and amyloid-targeted therapies over the forecast period. - North America is expected to remain the largest market in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period. - The company says its 2026 report set will continue to add forecasting and market-scoring tools for buyers.